Danicamtiv reduces myosin’s working stroke but activates the thin filament by accelerating actomyosin attachment

Proceedings of the National Academy of Sciences, Volume 122, Issue 34, August 2025. <br/>SignificanceHeart failure is a leading cause of death worldwide, and there is a need to develop new treatments that improve outcomes for patients. Recently, the myosin-binding small molecule danicamtiv entered clinical trials for treating heart failure; …